Seres Therapeutics, Inc.
NASDAQ:MCRBBiotechnology
+$0.11 today
- Market cap
- $51.13M
- Beta
- 0.11
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$4.89
Volume 0.04M
Average 0.06M
MCRB Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Seres Therapeutics, Inc.NASDAQ: MCRB
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $1.77M fell 37.4% year over year, ahead of the -43.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 44.8% from the prior quarter. Over 3 fiscal years it compounded at -24.8% a year.
Context
- Stock-based compensation amounted to 1373.9% of revenue in FY2025.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -37.4% holds above the trailing-twelve-month pace of -43.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 10.84M USD
- Year-over-year change
- -48.3%
- 4-year CAGR
- -14.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.84M | -48.3% |
| FY2024 | 2024-12-31 | 20.97M | -38.5% |
| FY2023 | 2023-12-31 | 34.1M | +33.8% |
| FY2022 | 2022-12-31 | 25.48M | +26.0% |
| FY2021 | 2021-12-31 | 20.22M | — |
Stock-Based Compensation vs competitors
How MCRB compares with its peers on the latest reported figures
- MCRB's LTM Mar 2026 stock-based compensation of $9.79M is the 2nd largest of the 9 companies compared; the peer median is $4.47M.
- Its year-over-year change of -43.4% is the 5th highest of 8, against a peer median of -42.1%.
- Stock-based compensation amounts to 853.3% of revenue for MCRB, versus a peer median of 33.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.88M | -49.1% | -22.9% | 85.6% | |
| LTM Mar 2026 | $9.79M | -43.4% | -24.8% | 853.3% | |
| LTM Mar 2026 | $9.77M | +1.5% | +47.6% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $6.28M | +111.2% | +109.9% | — |
| LTM Mar 2026 | $5M | — | +208.8% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $3.95M | +20.1% | +23.4% | 33.0% |
| LTM Mar 2026 | $3.88M | -47.0% | -22.0% | 7.1% | |
| LTM Mar 2026 | $3.06M | -44.1% | -45.0% | — | |
| LTM Mar 2026 | $1.83M | -42.1% | -16.4% | — | |
| Peer median (excluding MCRB) | $4.47M | -42.1% | +3.5% | 33.0% | |
Competitors are the stored peer set for MCRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (65.58M) | (250.16M) | (113.72M) | 136K | 5.7M |
| Depreciation & Amortization | 5.95M | 6.63M | 6.24M | 5.47M | 4.13M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.22M | 25.48M | 34.1M | 20.97M | 10.84M |
| Change in Working Capital | 41.53M | (18.39M) | (58.98M) | (65.51M) | (27.78M) |
| Accounts Receivables | 9.39M | 0 | (8.67M) | (2.07M) | 1.55M |
| Inventory | 0 | 0 | (29.65M) | (33.8M) | 0 |
| Accounts Payables | 9.36M | 2.2M | (11.58M) | (2.94M) | (2.4M) |
| Other Working Capital | 22.78M | (20.59M) | (9.08M) | (26.71M) | (26.93M) |
| Other Non-Cash Items | 4.57M | 7.62M | 15M | (109.68M) | 8.23M |
| Operating Cash Flow | 6.69M | (228.82M) | (117.35M) | (148.61M) | 1.12M |
| Capital Expenditures | (9.57M) | (9.82M) | (7.98M) | (380K) | (252K) |
| Acquisitions (Net) | 0 | (92.25M) | 0 | 0 | 210K |
| Purchases of Investments | (95.97M) | (48.22M) | (4.43M) | 13.52M | 0 |
| Sales of Investments | 169.63M | 140.47M | 22.98M | 142.67M | 0 |
| Other Investing Activities | 0 | 92.25M | 0 | (13.52M) | 0 |
| Investing Cash Flow | 64.09M | 82.43M | 10.58M | 142.29M | (42K) |
| Debt Repayment | (948K) | 25.7M | 50.52M | (127.91M) | 0 |
| Common Stock Issued | 2.13M | 101.17M | 18.16M | 23.53M | 13.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.13M | 2.74M | 3.03M | 14M | 0 |
| Financing Cash Flow | 1.18M | 129.6M | 71.71M | (90.37M) | 13.9M |
| Effect of Forex Changes | (1K) | (1K) | 2K | (1K) | 0 |
| Net Change in Cash | 71.95M | (16.79M) | (35.07M) | (96.69M) | 14.97M |
| Free Cash Flow | (2.88M) | (238.64M) | (125.33M) | (148.99M) | 865K |
Seres Therapeutics, Inc.
NASDAQ:MCRB
Intrinsic Alpha fair value
Locked
Current Price
$5.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.